



**31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management**

**August 23-26 2015**

**Hynes Convention Center, Boston, MA**

**Abstract Submission Deadline:**

**Monday, February 16, 2015, 11:59 PM, Central Standard Time**

**INSTRUCTIONS FOR COMPLETING THE ONLINE ABSTRACT FORM - Oral/Poster**

**Overview**

The 31<sup>st</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE 2015) is a unique forum for exchange of scientific information from the fields of pharmacoepidemiology and therapeutic risk management among those in the pharmaceutical industry, government, academia, service providers, regulators, consulting firms, health insurers, and contract research organizations. The meeting is acknowledged widely as the preeminent global conference on pharmacoepidemiology and therapeutic risk management. The agenda will be a combination of invited lectures, submitted research abstracts, posters, symposia and workshops - together representing the current state of experience and knowledge in these dynamic disciplines. The 2015 meeting will be held **August 23-26, 2015** in Boston, MA, USA. Please visit the ISPE website ([www.pharmacoepi.org](http://www.pharmacoepi.org)) for updated meeting information, scholarship information and forms, hotel information and registration forms.

The International Society for Pharmacoepidemiology (ISPE) is an international organization dedicated to advancing the health of the public by providing a forum for the open exchange of scientific information and for the development of policy, education, and advocacy for the field of pharmacoepidemiology, including such areas as pharmacovigilance, drug utilization research, comparative effectiveness research, and therapeutic risk management.

**INVITATION TO PRESENT YOUR RESEARCH**

We invite you to submit an abstract(s) for presentation at the ICPE 2015. Abstracts will be accepted for an oral/poster presentation or for a workshop/symposium. Abstracts are encouraged on research consistent with ISPE Special Interest Groups (SIGs): Adherence; Asian Pharmacoepidemiology Network (AsPEN); Biologics; Benefit Risk Assessment, Communication and Evaluation (BRACE); Comparative Effectiveness Research (CER); Databases; Drug Utilization/Health Services Research; Medical Devices; Medications in Pregnancy; Molecular Epidemiology/Biomarkers/Pharmacogenetics, Pediatrics, and Vaccines.

Results that have been published (except in abstract form) either on-line ahead of print, or in printed version before January 1, 2015 are not eligible for submission. Results that have been presented at meetings of other scientific societies are eligible for presentation, provided that they have not been published (except in abstract form) either on-line ahead of print, or in printed version before January 1, 2015.

All abstracts submitted and accepted will be published online in *Pharmacoepidemiology and Drug Safety*, ISPE's official journal.

## REVIEWING/REGISTRATION

All Abstracts will be evaluated by volunteers from the general membership of ISPE. The ISPE Scientific Program Committee will then review all abstracts considered for oral presentations in April 2015. This year ISPE will send two Email notifications to those submitters whose abstracts have been accepted: [1] a general letter of acceptance will be Emailed soon after the Mid-Year Meeting (anticipate receipt by the end of April); and [2] a second letter with specific session details will be sent after the agenda is set (anticipate receipt by late June). All presenters, panelists and moderators must register to attend the meeting.

## NEWCOMER TRACK - *Deadline: January 15, 2015*

The ICPE 2015 Scientific Program Committee offers a Newcomer Track for researchers submitting for the first time to the International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), regardless of native language or country of origin. The Newcomer Track includes useful information for preparing scientific abstracts. Researchers are encouraged to review these materials – posted in the form of a manuscript, slide presentation, and YouTube video – prior to submitting their draft abstract.

Researchers will receive feedback from a reviewer and will have the opportunity to resubmit their abstract before the February 16, 2015 deadline. Abstracts will be reviewed between mid-December and January 15. Early submission is encouraged to provide sufficient time for review and revision of the abstract. Abstracts submitted after the January 15 Newcomer Track deadline will automatically go through the standard abstract review process.

*All abstracts, regardless whether they have been reviewed previously in the Newcomer Track, must go through the standard ISPE review and selection process.*

## AWARDS

### 1. Student Awards

To recognize and encourage excellence in the scholarship of pharmacoepidemiology among students, ISPE will grant several student awards, that will be presented during the annual meeting. The Stanley A. Edlavitch Award is granted to the author of the best student abstract. Awards also are given for the second and third best student abstracts and the best methods abstract submitted by a student.

#### **Eligibility:**

- a) Applicant must be enrolled as a full-time student at the time of this submission.
- b) Applicant must be listed as the first author.
- c) Applicant must be a major contributor to the work.
- d) If the abstract is selected, applicant must make the presentation at the Conference.

Awardees will be notified by email in May 2015.

### 2. Andrew McAfee Award

The Andrew McAfee Award commemorates a passionate teacher, drug safety researcher and long-time active participant and supporter of ISPE who died in a tragic accident in 2010. It is granted to the best abstract submitted by a researcher or student living in a developing country.

### 3. John Snow Award

This award is granted to the best abstract submitted by a female researcher or student living in a developing

country.

### **SCHOLARSHIPS - Deadline March 4, 2015**

A limited number of scholarships will be available to assist with attendance at the ICPE 2015. Scholarships may be used for registration, lodging, and travel to the conference. Researchers from developing countries, those in genuine financial need, and students who otherwise would be unable to attend ICPE are invited to submit an application form. Applications can be found on the ISPE website ([www.pharmacoepi.org](http://www.pharmacoepi.org)). SUBMISSION DEADLINE: **March 4, 2015**. ISPE will notify applicants by email in May 2015. Please be aware that the scholarship submission, review and award process is independent from the abstract review and acceptance process.

### **SPONSORSHIPS, EXHIBITS & ACADEMIC SHOWCASE**

ISPE offers organizations, institutions, and academic programs opportunities to support the conference while sharing their products and services with conference attendees. A Conference Support Opportunities & Scientific Exhibition Prospectus is posted on the ISPE website or you may email ISPE ([ISPE@pharmacoepi.org](mailto:ISPE@pharmacoepi.org)) or call the ISPE office (301-718-6500) for more information.

### **GENERAL MEETING INFORMATION**

Meeting, hotel, registration and travel information will be posted on the ISPE website ([www.pharmacoepi.org](http://www.pharmacoepi.org)). This information will be updated over the coming months. Contact the ISPE office ([ISPE@pharmacoepi.org](mailto:ISPE@pharmacoepi.org)) or (301-718-6500) if you have questions.

### **A. GUIDE FOR ORAL OR POSTER PRESENTATION**

An oral or poster presentation represents original research that is presented as either a 10-minute podium talk or as a poster. Poster presentations may also be chosen for 3-min oral presentation as part of a Spotlight Poster Session.

The following will provide some guidance regarding the content of the structured abstract for an oral or poster presentation. This guide provides you with the expectations regarding content of your submission under the five major headings: Background, Objectives, Methods, Results, and Conclusions.

**Background:** One or two sentences that describe the clinical (or other) importance of the study question.

**Objectives:** The main objective(s) or study question should be explicitly stated (e.g., "To determine the rate of..."). If study was to test an a priori hypothesis, it should be stated.

**Methods:** Should include statements that address:

1. **Design:** Basic study design, source population, follow-up; For new analyses of existing data the dataset should be disclosed; statement of criterion standard if study of screening or diagnostic test and any blinding; analysis type (e.g., cost-effectiveness, cost-benefit, etc.) if an economic analysis. Matching and selection of controls, if relevant, also should be included.
2. **Setting:** To assist readers in determining the relevance of the findings to their own circumstances, the setting or source population should be described including statements regarding generalization to a larger or more representative population. This may include eligibility, inclusion/exclusion criteria, and for surveys and follow-up studies should include the number eligible versus the number/proportion remaining in the analysis.
3. **Exposures or interventions:** explicit naming of medications or other interventions. Non-proprietary names

should be used.

4. **Main outcome measures:** the primary and secondary outcome measurement(s) as determined prior to data collection. If hypothesis was formulated after data collection, this should be stated.
5. **Statistical analysis:** The statistical methods should be described.

**Results:** The main outcomes of the study should be provided and quantified, including confidence intervals and/or other significance tests. If differences are not significant, the clinically important difference sought should be stated and the confidence interval for the difference between the groups should be given. When risk changes or effect sizes are reported, absolute values should be included so that the reader can determine the absolute as well as relative impact of the result. Screening and diagnostic test studies should report sensitivity, specificity, and likelihood ratio and if predictive value or accuracy is given, prevalence or pretest likelihood should be provided.

**Conclusions:** Only those conclusions that are directly supported by the reported data should be provided, along with their implications (avoiding speculation and overstatement of findings). Emphasis should be given equally to positive and negative findings of equal scientific merit.

The final decision as to whether a presentation will be poster or oral will be made by the ICPE Scientific Program Committee.

If an abstract is accepted for presentation, one author or the author's designee must attend the conference to present the abstract to have it published in the conference program. All presenters are required to pay the conference registration fee upon acceptance of the abstract. Presenters not registered by the Early Bird Deadline will be removed from the Final Program. The presenter will be responsible for making travel arrangements and paying the cost of travel and lodging.

\* The total time allocated for each oral presentation is 15 minutes, which includes 10 minutes for the presentation and 5 minutes for discussion.

**B. DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST** All presenters must disclose the financial and any other interests of each author that may pose a conflict of interest or the appearance of a conflict of interest. A sample disclosure slide/form will be posted on the ICPE 2015 home page.

## ONLINE SUBMISSION NOTES

This section contains information to guide you through the online submission process. We recommend that you print this page and use it as a reference during this process.

- Click the buttons on the left side of the screen and complete each section. Be sure to carefully follow the instructions within each section.
- Save your work by clicking Save Information. This does not submit your abstract for review. Be sure to save your work before logging off the site.
- You can log off at any time without submitting your abstract and return to continue your work at another time. As long as you do not submit the abstract, it can be edited and revised online as many times as needed. If you give your username and password to another person, they will have access to edit all abstracts you

have not submitted for review.

- Verify that your abstract is correct and complete by clicking Preview Abstract. Print out and proofread the abstract preview to verify that it is correct before completing the submission process.
- Click on Submit Your Abstract to submit your abstract for review, but **ONLY** do so when you are sure that your abstract is complete and in final form.